Vertex Pharmaceuticals (VRTX -2.12%) already brings in billions of dollars annually, thanks to its cystic fibrosis (CF) drugs. The company recently proved it could expand beyond the specialty area when it won approval with partner CRISPR Therapeutics for a gene editing therapy for blood disorders.Next, Vertex is about to show that it can conquer one of the world's most common health problems: pain. The company recently reported positive phase 3 data for VX-548, its treatment candidate for moderate-to-severe ...

Vertex Pharmaceuticals (VRTX) announced positive results from three late-stage studies on its investigational orally-administered non-opioid pain medicine, VX-548, to treat moderate-to-severe acute pain.The company evaluated VX-548, a novel first-in-class NaV1.8 inhibitor, in two pivotal phase III acute pain studies — one following bunionectomy surgery and the other following abdominoplasty surgery. The studies achieved their primary endpoint — treatment with VX-548 showed a significant reduction in pain in ...

The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $4.08 per share, indicating an increase of 8.5% compared to the year-ago period. Analysts forecast revenues of $2.5 billion, representing an increase of 8.5% year over year.The consensus EPS estimate for the quarter has undergone an upward revision of 0.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during ...

Good news from the lab sparked a mini-rally in Vertex Pharmaceuticals (VRTX 2.35%) stock on Tuesday. The biotech's shares closed the trading session more than 2% higher in price, which was good enough to top the flat-lining S&P 500 index. One of the company's investigational drugs is showing decent promise in a clinical trial.Pain drug meets primary endpoint in studyVertex announced that its VX-548, a non-opioid medication aimed at treating moderate to severe acute pain, met its primary endpoint in a phase ...

A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston on Oct. 23, 2019.Vertex Pharmaceuticals on Tuesday said its experimental painkiller, which is being tested as an alternative to addictive opioids, significantly decreased post-surgery pain in late-stage trialsThe drug, known as VX-548, did not work better than a popular opioid, however.Still, the trial results bring the biotech company one step closer to developing a drug that can provide strong pain relief without the addic ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double-blind, placebo-controlled, pivotal trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range of surgical a ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $435.82, with a +1.31% movement compared to the previous day. This change outpaced the S&P 500's 0.76% gain on the day. Elsewhere, the Dow gained 0.59%, while the tech-heavy Nasdaq added 1.12%.Shares of the drugmaker have appreciated by 5.72% over the course of the past month, outperforming the Medical sector's gain of 1.57% and the S&P 500's gain of 2.5%.The upcoming earnings release of Vertex Pharmaceuticals will be of great interest to inv ...

I'll readily admit that I've picked some supposed growth stocks in the past that didn't deliver much growth. The good news, though, is that my winners have far outpaced my losers over the long run.One of my mistakes has been to rely on wishful thinking. I've bought stocks that had potential but weren't anywhere close to being profitable yet and had valuations that weren't easily justified. A smarter approach, based on my experience, is to insist on potential, profits, and a reasonable price tag. My top grow ...

Those who put money in Vertex Pharmaceuticals (VRTX 0.57%) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period.However, a lot has changed for the biotech in the meantime, and as we all know, past success isn't a guarantee of anything. Can Vertex pull off another market-beating performance through the next decade? Let's dig into what's going on with the biotech and determine where it might be in 10 years. Vertex's core area is still a growth driverIn the pas ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) .Vertex currently has an average br ...